Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED AUGUST 2009. Refer to TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | sorafenib (Nexavar®) | |
| Formulation | 200 mg film-coated tablet | |
| Reference number | 287 | |
| Indication | Treatment of advanced renal cell carcinoma in patients who have failed prior interferon-α or interleukin-2 based therapy or are considered unsuitable for such therapy |
|
| Company | Bayer Healthcare Pharmaceuticals | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 14/03/2007 | |
| Ratification by Welsh Government | 04/06/2007 | |
| Date of issue | 29/06/2007 | |
| NICE guidance | ||